A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Bortezomib; Carfilzomib; Clarithromycin; Cyclophosphamide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Oncotherapeutics.
- 26 Aug 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 26 Aug 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 05 Jun 2018 Results (n=35) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History